LCM
NUVB icon

Legato Capital Management’s Nuvation Bio NUVB Stock Holding History

Legato Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
+228,193
New +$1.12M 0.11% 280

Other funds holding NUVB

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Legato Capital Management's NUVB Position: Q2 2026 in Review

Legato Capital Management opened a new position in Nuvation Bio (NUVB) in Q2 2026: 228,193 shares worth $1.3M. The stake represents 0.11% of the portfolio and ranks #280 among its holdings.

66 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Legato Capital Management held 228,193 shares of Nuvation Bio worth $1.3M as of Q2 2026.
  • Nuvation Bio was a new Legato Capital Management position in Q2 2026.
  • Nuvation Bio made up 0.11% of Legato Capital Management's portfolio in Q2 2026, its #280 holding.
  • 66 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.